Home/Pipeline/uTomo Platform Development

uTomo Platform Development

Neurological and Psychiatric Conditions (Digital Biomarkers/Diagnostics)

Pre-clinicalActive

Key Facts

Indication
Neurological and Psychiatric Conditions (Digital Biomarkers/Diagnostics)
Phase
Pre-clinical
Status
Active
Company

About XENSE

XENSE is an early-stage, private AI/ML diagnostics company targeting the neurology and psychiatry markets with its uTomo platform for advanced X-ray imaging. The company is in a pre-revenue, pre-clinical development stage and is currently raising capital from accredited investors via platforms like Wefunder and StartEngine. Leadership includes founder Ying Zhao as CEO/CTO and Dr. Sean Lavine heading Medical Affairs, indicating a blend of technical and clinical expertise. The primary near-term goals appear to be technology development, validation, and securing initial funding.

View full company profile

Therapeutic Areas